Publication | Closed Access

Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?

Rheumatoid DisorderRheumatologyBiopure RegistrySpondyloarthritisRheumatic DiseasesPsoriatic ArthritisOutcomes ResearchPatient-reported OutcomeInflammatory Rheumatic DiseaseMedicineRheumatoid Arthritis